
|Articles|July 17, 2008
Galderma approved for Differin(R) Gel 0.1 percent in Japan
Lausanne, Switzerland - Galderma Pharma S.A. announced that Japan’s Health Labor and Welfare has approved Differin(R) Gel 0.1 percent (adapalene).
Advertisement
Lausanne, Switzerland
- Galderma Pharma S.A. announced that Japan’s Health Labor and Welfare has approved Differin(R) Gel 0.1 percent (adapalene).
The drug, used to treat acne vulgaris, will be marketed in Japan by Galderma KK, the Japanese arm of Galderma.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Phase 3 Data Position Zasocitinib as a Potential New Oral Option for Psoriasis
2
Highlighting Major Breakthroughs for Atopic Dermatitis and Psoriasis in 2025
3
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
4
Topicals Demonstrate Targeted Control Across 3 Distinct Atopic Dermatitis Cases
5

















